Compare Recursion Pharmaceuticals Inc (RXRX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Recursion Pharmaceuticals Inc trades at $4.09 (market cap $2.14B), while Western Alliance Bancorporation trades at $74.34 (market cap $8.24B). The key difference: Western Alliance Bancorporation is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and Western Alliance Bancorporation pays a 2.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Western Alliance Bancorporation for 3 Days on average.
| RXRX | WAL | |
|---|---|---|
Market Cap | $2.14B | $8.24B |
Volume | 30,789,535 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $6.79 | $96.08 |
52-Week Low | $2.84 | $66.70 |
Typical Hold Time | 22 Days | 3 Days |
Enterprise Value | $1.66B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Western Alliance Bancorporation (WAL) trades at $74.22, down 0.17% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings have mostly beaten expectations. The company launched WA VenueX, an institutional financial platform, signaling innovation in digital banking services. Analyst consensus is strongly bullish with a $84.33 price target, though technical indicators suggest near-term caution.
WAL presents a compelling value opportunity with attractive valuation multiples and solid profitability, but faces headwinds from bearish technical trends and interest rate sensitivity. The stock's upside hinges on continued earnings growth and successful execution of new initiatives like WA VenueX, while regulatory changes and economic conditions remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
